LAKE FOREST, Ill., June 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%. Douglas Boothe, Akorn’s P...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.